Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer

NCT00386516 is registered in ClinicalTrials.gov with Galectin Therapeutics Inc. as lead sponsor.

NCT NCT00386516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00386516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer
Lead sponsor
Galectin Therapeutics Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2006
Completion date
June 30, 2009
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the bile duct, gallbladder cancer